share_log

Brookline Capital Initiates Coverage On Oncternal Therapeutics with Buy Rating, Announces Price Target of $16

Brookline Capital Initiates Coverage On Oncternal Therapeutics with Buy Rating, Announces Price Target of $16

Brookline Capital以买入评级启动Oncternal治疗药物的覆盖范围,宣布目标价为16美元
Benzinga Real-time News ·  2021/03/30 22:05

Brookline Capital analyst Kumaraguru Raja initiates coverage on Oncternal Therapeutics (NASDAQ:ONCT) with a Buy rating and announces Price Target of $16.

Brookline Capital分析师Kumaraguru Raja发起Oncternal Treeutics(纳斯达克:ONCT),买入评级,并宣布目标价为16美元。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发